Highlights MannKind Corporation

Equities

MNKD

US56400P7069

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 17:55:03 13/05/2026 BST			5-day change	1st Jan Change
3.215 ^USD	-1.98%		-9.33%	-43.07%

05-07	MannKind Corporation, Q1 2026 Earnings Call, May 06, 2026
05-06	Earnings Flash (MNKD) MannKind Corporation Posts Q1 Adjusted Loss $0.02 per Share	MT

Highlights

05-06	Earnings Flash (MNKD) MannKind Corporation Posts Q1 Adjusted Loss $0.02 per Share	MT
05-06	Earnings Flash (MNKD) MannKind Corporation Reports Q1 Revenue $90.2M, vs. FactSet Est of $105.4M	MT
05-06	MannKind Corporation Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
03-09	MannKind Corporation to Present New Data from Pediatric and Adult Studies of Afrezza at ATTD 2026	CI
03-05	MannKind Reports Convertible Notes Settlement	MT
02-26	MannKind Corporation Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
02-26	MannKind Shares Decline After Q4 Adjusted Earnings Fall	MT
02-26	MannKind Q4 Adjusted Earnings Fall, Revenue Rises	MT
02-26	Earnings Flash (MNKD) MannKind Corporation Reports Q4 Revenue $112.0M, vs. FactSet Est of $97.6M	MT
02-26	Earnings Flash (MNKD) MannKind Corporation Posts Q4 Adjusted EPS $0.01 per Share, vs. FactSet Est of $0.05	MT
02-09	Mannkind Corporation Announces First Patient Enrolled in Inhale-1St Pediatric Study Evaluating Afrezza®? for Youth with Newly-Diagnosed Type 1 Diabetes	CI
01-26	MannKind Corporation Announces FDA Approval of Updated Afrezza Label Providing Starting Dose Guidance When Switching from Multiple Daily Injections or Insulin Pump Mealtime Therapy	CI
01-26	MannKind announces FDA approval of updated Afrezza label providing starting dose guidance when switching from multiple daily injections (MDI) or insulin pump mealtime therapy	RE
12-23	MannKind Corporation Shares FUROSCIX®? Business Updates	CI
12-01	MannKind announces U.S. FDA accepts for review its supplemental new drug application (sNDA) of Furoscix Readyflow(TM) autoinjector	RE
12-01	MannKind Corporation Announces U.S. FDA Accepts for Review its Supplemental New Drug Application of FUROSCIX ReadyFlow Autoinjector for the Treatment of Edema in Adults with Chronic Kidney Disease	CI
11-10	MannKind Corporation Announces Discontinuing its Phase 3 Clinical Trial Evaluating Nebulized Inhalation Suspension of Clofazimine	CI
11-05	MannKind Shares Rise After Q3 Beat	MT
11-05	MannKind Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
11-05	MannKind's Q3 Non-GAAP Net Income, Revenue Rise	MT
11-05	Biopharma MannKind's Q3 revenue up 17%	RE
11-05	Earnings Flash (MNKD) MannKind Corporation Reports Q3 Revenue $82.1M, vs. FactSet Est of $80.2M	MT
11-05	Earnings Flash (MNKD) MannKind Corporation Posts Q3 Adjusted EPS $0.07 per Share, vs. FactSet Est of $0.03	MT
13/10/25	Mannkind Corporation Announces U.S. Fda Accepts for Review Its Supplemental Biologics License Application for Inhaled Insulin in Children and Adolescents Aged 4-17 Years Living with Diabetes	CI
13/10/25	MannKind announces US FDA accepts for review its sBLA for inhaled insulin	RE